In accordance with Article 10 of the Corporate Governance Communiqué ("Communiqué") of the Capital Markets Board No. II-17.1, the conclusion section of the "Report on Common and Continuous Related Party Transactions" ("Report") prepared by our Company's Board of Directors is presented below for the information of our shareholders.
The Conclusion Section of the Report:
In accordance with Article 10 of the Corporate Governance Communiqué ("Communiqué") of the Capital Markets Board No. II-17.1, within the framework of the agreements concluded between Eczacıbaşı İlaç Pazarlama A.Ş. ("EİP") and Gensenta İlaç Sanayi ve Ticaret A.Ş. ("Gensenta"), both of which are subsidiaries of our Company, that designates EİP as the authorized company responsible for the domestic distribution, promotion, marketing and sales of various products for which Gensenta is licensed, the total amount of the purchase and sale transactions of common and continuous goods carried out during 2024 has reached more than 10% of the revenue and the cost of good sold amount included in the consolidated financial statements of our Company for 2024 and is expected to reach more than 10% in 2025; the conditions of the transactions that are expected to be continued under similar conditions in 2025, the method of price determination and the reasons for choosing this method were explained, and it was concluded that the transactions were in accordance with the market conditions.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.